Multi-omics analysis of the effect and mechanism of sodium-glucose cotransporter 2 inhibitors on metabolic dysfunction-associated fatty liver disease

被引：0
|
作者：
Chen, J. [1 ,2 ]
Du, J. [1 ]
Sun, Q. [1 ]
Zhang, M. [1 ]
Haoming, T. [2 ]
机构：
[1] Univ Elect Sci & Technol China, Sichuan Prov Peoples Hosp, Dept Geriatr Med, Chengdu, Peoples R China
[2] Sichuan Univ, Dept Endocrinol, West China Hosp, Chengdu, Peoples R China
来源：
DIABETOLOGIA | 2024年 / 67卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
970
引用
收藏
页码：S462 / S462
页数：1
相关论文
共 50 条
  • [1] Sodium-glucose Cotransporter 2 Inhibitors and Nonalcoholic Fatty Liver Disease
    Salah, Husam M.
    Fudim, Marat
    HEART FAILURE CLINICS, 2022, 18 (04) : 625 - 634
  • [2] Metabolic dysfunction-associated steatotic liver disease - A new indication for sodium-glucose Co-transporter-2 inhibitors
    Procyk, Grzegorz
    Jaworski, Jakub
    Gasecka, Aleksandra
    Filipiak, Krzysztof J.
    Borovac, Josip A.
    ADVANCES IN MEDICAL SCIENCES, 2024, 69 (02): : 407 - 415
  • [3] Rise of sodium-glucose cotransporter 2 inhibitors in the management of nonalcoholic fatty liver disease
    Dokmak, Amr
    Almeqdadi, Mohammad
    Trivedi, Hirsh
    Krishnan, Sandeep
    WORLD JOURNAL OF HEPATOLOGY, 2019, 11 (07) : 562 - 573
  • [4] Rise of sodium-glucose cotransporter 2 inhibitors in the management of nonalcoholic fatty liver disease
    Amr Dokmak
    Mohammad Almeqdadi
    Hirsh Trivedi
    Sandeep Krishnan
    World Journal of Hepatology, 2019, (07) : 562 - 573
  • [5] THROMBOSPONDIN 2: A KEY PLAYER IN FIBROGENESIS OF METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE UNCOVERED BY MULTI-OMICS ANALYSIS
    Kimura, Takefumi
    Wakabayashi, Shun-Ichi
    Tanaka, Naoki
    Umemura, Takeji
    HEPATOLOGY, 2024, 80 : S569 - S570
  • [6] THE EFFECT OF SODIUM-GLUCOSE COTRANSPORTER-2 ON NONALCOHOLIC FATTY LIVER DISEASE
    Kuhareva, Elena
    Mankieva, Eliza
    Tarasova, Olga
    Moyam, Yannick Ngameni
    GASTROENTEROLOGY, 2023, 164 (06) : S1433 - S1433
  • [7] The cellular and molecular mechanisms mediating the protective effects of sodium-glucose linked transporter 2 inhibitors against metabolic dysfunction-associated fatty liver disease
    Ao, Na
    Du, Jian
    Jin, Shi
    Suo, Linna
    Yang, Jing
    DIABETES OBESITY & METABOLISM, 2024,
  • [8] Multi-omics analyses of the gut microbiota and metabolites in children with metabolic dysfunction-associated steatotic liver disease
    Du, Landuoduo
    Zhang, Kaichuang
    Liang, Lili
    Yang, Yi
    Lu, Deyun
    Zhou, Yongchang
    Ren, Tianyi
    Fan, Jiangao
    Zhang, Huiwen
    Wang, Ying
    Jiang, Lu
    MSYSTEMS, 2025,
  • [9] Unexpected metabolic effects of sodium-glucose cotransporter 2 inhibitors
    Drueke, Tilman B.
    Massy, Ziad A.
    KIDNEY INTERNATIONAL, 2024, 106 (01) : 12 - 15
  • [10] Sodium-glucose co-transporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors on major liver outcomes in metabolic dysfunction-associated steatotic liver disease
    Shen, Tsung-Hua
    Aby, Elizabeth S.
    Vock, David
    Farley, Joel F.
    DIABETES OBESITY & METABOLISM, 2024, 26 (11): : 5116 - 5125
12345